Mass. Movers

Alnylam releases trial results


Alnylam Pharmaceuticals Inc. released top-line results from its phase 2b trial for its treatment of respiratory syncytial virus, an infection in lung transplant patients. The Cambridge company said the trial was a randomized, double-blind, placebo-controlled study of the drug, ALN-RSV01, in infected lung transplant patients. “We believe that these data provide important evidence’’ of a reduction in the incidence of new disease in patients, said one Alnylam executive.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of